ELUCIDATION OF PELAREOREP PHARMACODYNAMICS IN A PHASE I TRIAL IN PATIENTS WITH KRAS MUTATED COLORECTAL CANCER

KRAS mutation is a negative predictive biomarker of anti-EGFR agents in patients with metastatic colorectal cancer (mCRC), and remains an elusive target. Pelareorep, a double-stranded RNA virus selectively replicates in KRAS mutated cells, and is synergistic with irinotecan. A dose escalation trial...

全面介紹

Na minha lista:
書目詳細資料
發表在:Mol Cancer Ther
Main Authors: Goel, Sanjay, Ocean, Allyson J., Parakrama, Ruwan Y., Ghalib, Mohammad H., Chaudhary, Imran, Shah, Umang, Viswanathan, Sengottuvel, Kharkwal, Himanshu, Coffey, Matthew, Maitra, Radhashree
格式: Artigo
語言:Inglês
出版: 2020
主題:
Article
在線閱讀:https://ncbi.nlm.nih.gov/pmc/articles/PMC7207225/
https://ncbi.nlm.nih.gov/pubmed/32156785
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1535-7163.MCT-19-1117
標簽: 添加標簽
沒有標簽, 成為第一個標記此記錄!

相似書籍